Gastric Electrical Stimulators Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa

The global gastric electrical stimulators market is projected to witness significant expansion, reaching a value of US$450.2 Mn by 2032, up from US$280.2 Mn in 2025. This growth is expected to occur at a steady CAGR of 7.01% from 2025 to 2032, fueled by the growing prevalence of gastroparesis and obesity, and increasing interest in non-invasive, technologically advanced treatment options.

Market Insights

Gastric electrical stimulation (GES), also known as gastric pacing, involves the implantation of a small neurostimulator device under the skin. This device delivers mild electrical pulses to the stomach muscles through leads placed in the stomach wall. It is particularly useful for patients with gastroparesis—a chronic digestive disorder—and for individuals struggling with obesity when other treatments prove ineffective.

As awareness of digestive health increases and innovations in medical devices continue to evolve, GES is gaining traction as a valuable treatment alternative for patients who are not responding well to traditional therapies.

Market Drivers
• Increasing Gastroparesis Cases: Growing diagnosis of gastroparesis, especially among diabetic patients, is a major driver. Symptoms like delayed gastric emptying are becoming more prevalent worldwide.
• Rising Obesity Rates: Global obesity levels have surged over the years, increasing the demand for non-pharmacological and minimally invasive weight-loss interventions such as GES.
• Technological Breakthroughs: The introduction of rechargeable, wireless, and smaller-sized stimulators is improving patient comfort, making treatments more accessible and attractive.
• Supportive Reimbursement and Healthcare Policies: Particularly in developed nations, policies that cover GES treatments are promoting greater adoption among patients and healthcare providers.

Market Challenges
• Complications and Risks: Risks such as infection, bleeding, lead dislocation, or device failure continue to be concerns limiting faster adoption.
• Limited Regulatory Approvals for Obesity: While GES is approved for treating gastroparesis, regulatory approval for obesity treatment remains restricted in many regions.
• Availability of Alternatives: Other surgical and pharmaceutical treatments may slow down the adoption of GES in some patient segments.

Emerging Opportunities

Innovations in device development, including endoscopically implantable and wirelessly rechargeable stimulators, are reshaping the treatment Analysis. As medical technology becomes more personalized and less invasive, companies investing in R&D are expected to lead market growth.

Moreover, integration of GES with IoT-based platforms for monitoring and remote diagnostics is expected to attract significant attention and investment. These digital advancements are enhancing the overall functionality and efficiency of gastric stimulation therapy.

Regional Overview
• North America: The region remains at the forefront, led by the US, due to the high prevalence of gastroparesis, growing adoption of minimally invasive surgeries, and a favorable reimbursement structure.
• Asia Pacific: A rapidly growing healthcare infrastructure, increasing geriatric population, and rising rates of obesity and diabetes are contributing to substantial market opportunities across countries like China, India, and Japan.
• Europe: Technological innovation continues to drive demand, although regulatory hurdles related to obesity treatment applications pose limitations.
• Latin America and the Middle East & Africa: These regions are gradually adopting advanced medical technologies, with market growth supported by awareness initiatives and an improving healthcare ecosystem.

Key Market Players

Several leading companies are actively contributing to market development through product innovation, partnerships, and expansion strategies. Notable players include:
• Medtronic Plc.
• IntraPace Inc.
• ReShape Lifesciences Inc.
• Changzhou Ruishen Medical Equipment Co. Ltd.
• Chen Tao Medical Equipment
• Rishena Co. Ltd.
• Enterra™

In a significant advancement, IntraPace introduced the INSPIRES Control wireless gastric stimulator in 2021, offering a non-invasive and patient-centric solution that eliminates the need for surgery during device insertion and removal. Medtronic also launched the Enterra II 37800 gastric neurostimulator, designed to treat severe nausea and vomiting in patients with drug-resistant gastroparesis.

Market Impact of Product Innovations

These new products mark a shift toward more efficient and user-friendly treatments. The introduction of wireless and programmable technologies is expanding access, increasing adoption rates, and redefining the market’s direction by offering alternatives to traditional surgical interventions.

Market Segmentation

By Type
• High Frequency
• Low Frequency

By Application
• Gastroparesis
• Obesity

By End User
• Hospitals
• Ambulatory Surgical Centers
• Other End Users

By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Please note: Delivery Timelines - 5 working days.